Immunodiagnostics Market Size, Share and Industry Analysis By Product Instruments, Reagents & Consumables), By Application (Oncology & Endocrinology, Hepatitis & Retrovirus, Cardiac Markers, Infectious Diseases), By End user (Clinical Laboratories, Hospitals, Physician’s Offices), By End-user(Hospitals, Dental Clinics, Academic & Research Institutes) and Regional Forecast, 2026-2034

The immunodiagnostics market size was valued at USD 23.52 billion in 2025. The market is projected to grow from USD 24.99 billion in 2026 to USD 44.83 billion by 2034, exhibiting a CAGR of 7.58% during 2026-2034. North America dominated the immunodiagnostics market with a market share of 37.02% in 2025. 

Immunodiagnostics is a branch of in-vitro diagnostics with high sensitivity, which has led to the emergence of prospective diagnostic technologies, diagnostic platforms, and new immunoassay formats. The Enzyme-Linked Immunosorbent Assay (ELISA) and Radioimmunoassay (RIA) have been the predominant techniques since the initial era of immunodiagnostics.

The market is expected to grow rapidly during the forecast period, owing to the increasing incidence & prevalence of infectious diseases such as cancer, respiratory infections, hepatitis, HIV infection, and other infectious diseases. The rise in geriatric population, technological advancements in diagnostic kits and rising utilization of immunodiagnostics in rapid point of care testing devices are some of the factors expected to drive the market during 2026-2034.

Download Free sample to learn more about this report.

Immunodiagnostics Market KEY TAKEAWAYS

Global Market Size & Forecast

• 2025 Market Size: USD 23.52 billion
• 2026 Market Size: USD 24.99 billion
• 2034 Forecast Market Size: USD 44.83 billion
• CAGR: 7.58% from 2026–2034

Market Share

• North America held a 37.02% market share in 2025.
• Oncology & Endocrinology accounted for 25.60% of the market in 2024.
• Reagents & consumables are expected to be the fastest-growing product segment.

Key Regional Highlights

North America

North America held a 37.02% market share in 2025.

Asia Pacific

Asia Pacific accounted for 24.60% of the market in 2025.

Europe

Europe represented 24.52% of the market in 2025.

U.S.

U.S.: Rising product approvals and healthcare spending are driving market growth.

Japan

Japan: Growing demand for advanced diagnostic testing supports market expansion.

Read More

MARKET DYNAMICS

Market Drivers

Rising Prevalence of Infectious and Chronic Diseases to Drive Market Growth

The growing global burden of infectious diseases (HIV, hepatitis, tuberculosis, and emerging pathogens) alongside chronic conditions such as cancer, cardiovascular disease, and autoimmune disorders is fueling demand for accurate and early diagnostic testing. Immunodiagnostic assays - including ELISA, chemiluminescence immunoassay (CLIA), and rapid tests - are increasingly used for early detection, disease monitoring, and treatment response tracking, positioning them as essential tools across clinical and laboratory settings.

Download Free sample to learn more about this report.

Market Restraints

High Cost of Advanced Immunodiagnostic Systems to Restrain Market Growth

Sophisticated immunoassay analyzers and reagents involve substantial capital investment, which limits adoption among small and mid-sized diagnostic laboratories, particularly in low- and middle-income countries. Recurring costs of reagents, calibrators, and maintenance further add to the total cost of ownership, constraining market penetration in cost-sensitive regions.

Market Opportunities

Integration of AI and Automation in Immunodiagnostics to Offer Lucrative Opportunities

The convergence of artificial intelligence, automation, and immunodiagnostics is opening new avenues for improved accuracy, throughput, and workflow efficiency. AI-powered result interpretation, automated sample handling, and cloud-connected diagnostic platforms are enabling laboratories to scale testing capacity while reducing turnaround time and human error.

Market Challenges

Stringent Regulatory Landscape and Standardization Issues to Pose Challenges

Variability in regulatory requirements across regions (FDA, CE-IVDR, and other national bodies) creates complexity for manufacturers seeking global market entry. Additionally, lack of standardization across assay platforms can lead to inconsistent results across laboratories, undermining clinical trust and slowing adoption of newer technologies.

Segmentation Analysis 

Oncology & Endocrinology is the Attractive Application Type

Oncology & Endocrinology segment accounted for a market share of 25.6% in 2025. The highest share of the segment is attributed to the adoption of immunodiagnostics in several applications such as cancer and endocrine disease. Increase in the number of new product approvals, and adequate reimbursement for products and tests are expected to drive the overall immunodiagnostics market during the forecast period. For instance, in Nov 2024, OPKO Health Inc. received approval from the U.S. Food and Drug Administration (FDA) for the total prostate-specific antigen test with the immunoassay analyzer. 

To know how our report can help streamline your business, Speak to Analyst

In terms of product types, the reagents & consumables segment is likely to be the fastest-growing segment during the forecast period, owing to the high replacement rate and several consumables are single-use products. Based on end users, clinical laboratories segment is likely to be the fastest-growing segment for the forecast duration owing to the gradual shift of testing from hospitals and clinical laboratories.

Regional Analysis

North America

North America Emerges as Lucrative Market for Immunodiagnostics

To get more information on the regional analysis of this market, Download Free sample

North America contributed approximately USD 8.71 billion to the global market in 2025, accounting for 37.02% share, and is expected to reach USD 9.23 billion in 2026. and is anticipated to register a comparatively higher CAGR during 2025 to 2032 due to the rising prevalence of infectious diseases, an increase in the number of new product approvals, and adequate reimbursement for products and tests in the region. Moreover, the aging population, rising healthcare expenditures, increasing emphasis on better patient outcomes, and huge patient pool are the factors considered to support the immunodiagnostics market growth in North America during the forecast period. 

At present, developed nations hold a dominant share and are considered to grow slowly compared to emerging markets during the forecast period.

Europe 

In 2025, the Europe market stood at USD 5.77 billion, representing 24.52% of global demand, and is projected to grow to USD 6.12 billion in 2026.

Asia Pacific

The Asia Pacific region captured 24.60% of the global market in 2025, generating USD 5.79 billion in revenue, and is projected to reach USD 6.24 billion in 2026.

Latin America

Latin America recorded a market size of USD 1.91 billion in 2025, capturing 8.12% of the global market share, and is projected to reach USD 2 billion in 2026.

Middle East & Africa

In 2025, Middle East & Africa generated USD 1.35 billion, contributing 5.73% to global market revenue, and is projected to grow to USD 1.41 billion in 2026.

Key Market Drivers 

"Abbott, Roche Diagnostics, & DiaSorin Expected to Hold Considerable Share in the Global Market "

Giant organizations such as Abbott, Roche Diagnostics, Danaher Corporation, & DiaSorin are expected to lead the market during the forecast period. Optimal research & development strategies, robust supply chain network, increasing investments in research & development, and cost management are projected to serve as huge opportunities for the aforementioned market players to lead the global market during the forecast period. Moreover, a higher potential for intense penetration of immunodiagnostics in the Asia Pacific market may offer significant share for the companies in terms of revenue in the global immunodiagnostics market. 

Key companies covered in the report

• Abbott
• Hoffmann-La Roche AG (Roche Diagnostics)
• DiaSorin
• Danaher Corporation
• QIAGEN
• bioMérieux
• Thermo Fisher Scientific
• Quest Diagnostics

Report Overview

At present, developed nations account for the largest immunodiagnostics market share, owing to factors such as growing emphasis on early diagnosis and prevention from diseases by government organizations. Advances in diagnostics testing and changing patient preferences leading to a gradual shift of testing from hospitals and commercial laboratories more towards the point of care is expected to have a higher impact on the growth of the market. 

The report provides qualitative and quantitative insights in immunodiagnostics industry and detailed analysis of market size & growth rate for all possible segments in the market. The market is segmented by product type, application, and end user. On the basis of product type, the global market is categorized into instruments and reagents & consumables. Based on the application, the market is segmented into oncology & endocrinology, hepatitis & retrovirus, cardiac markers, infectious diseases, and others. 

Various end users covered in the report are hospitals, Clinical laboratories, and physician offices and others. Geographically, the immunodiagnostics market is segmented into five major regions, which are North America, Europe, Asia Pacific, and Latin America, and Middle East & Africa. The regions are further categorized into countries. 

Along with this, the report provides elaborative analysis of market dynamics and competitive landscape. Various key insights provided in the report are key brand analysis, key industry developments - mergers, acquisitions and partnerships, reimbursement scenario, and key performance indicators for global immunodiagnostics market

Request for Customization   to gain extensive market insights.

Report Scope & Segmentation

Key Industry Developments

• In March 2019, Oncimmune announced the acquisition of Protagen Diagnostics.
• In November 2018, Ortho Clinical Diagnostics received U.S FDA approval for the company’s VITROS HIV Combo test, an immunodiagnostic detect HIV-1 and HIV-2 antibodies (Ab) and the p24 antigen (Ag).
• In May 2016, Diasorin announced the acquisition of Quest Diagnostics’ immunodiagnostics products.